{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:06:38Z","timestamp":1793844398732,"version":"4.6.1"},"reference-count":32,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004690","name":"Minist\u00e8re de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004690","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,3,5]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. Rituximab is now recommended as first-line therapy for membranous nephropathy. However, Kidney Disease Improving Global Outcomes guidelines do not recommend any specific protocol. Rituximab bioavailability is reduced in patients with membranous nephropathy due to urinary drug loss. Underdosing of rituximab is associated with treatment failure. We have previously developed a machine learning algorithm to predict the risk of underdosing. We have retrospectively shown that patients with a high risk of underdosing required higher doses of rituximab to achieve remission. The aim of this prospective study is to evaluate the efficacy of algorithm-driven rituximab treatment in patients with membranous nephropathy compared to standard treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre, randomised, controlled, open-label, prospective superiority clinical trial will be conducted in 13 French hospitals. 130 consecutive patients with primary membranous nephropathy and active nephrotic syndrome will be randomised to either the standard protocol control group (two 1 g rituximab infusions on days 0 and 15) or the algorithm-driven rituximab treatment group. In the latter, the rituximab dose will depend on the algorithm-estimated risk of underdosing. Patients with an algorithm-estimated risk of underdosing \u226450%\u2009will receive 1 g of rituximab on days 0 and 15. Patients with an algorithm-estimated risk of underdosing between 51% and 75% will receive 1 g of rituximab on days 0, 15 and 30. Finally, patients with an estimated risk of underdosing &gt;75%\u2009will receive 1 g of rituximab on days 0, 15, 30 and 45. The primary study outcome is the rate of clinical remission (complete or partial) at month 6 after treatment initiation. The secondary outcomes include clinical remission at month 12, immunological remission, proteinuria, albuminuria, serum creatinine, estimated glomerular filtration rate, phospholipase A2 receptor type 1 antibody titre, anti-rituximab antibody occurrence, lymphocyte count, serum rituximab level and related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial received ethics approval from the local ethics boards. The results of this study will confirm whether algorithm-driven rituximab treatment is more effective in inducing remission than the standard regimen and thus may contribute to improving management of patients with membranous nephropathy. The results of our study will be submitted to a peer-review journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06341205\">NCT06341205<\/jats:ext-link>\n                      trial number. Registered on 2 April 2024.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-093920","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T02:16:27Z","timestamp":1743646587000},"page":"e093920","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06341205","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01508468","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03804359","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06341205","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01508468","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01180036","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01955187","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03018535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3601-0572","authenticated-orcid":false,"given":"Maxime","family":"Teisseyre","sequence":"first","affiliation":[{"name":"Institut de Recherche sur le Cancer et Vieillissement UMR7284 CNRS INSERM U1081, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Centre de R\u00e9f\u00e9rence Maladies Rares Syndrome N\u00e9phrotique Idiopathique et Glom\u00e9rulon\u00e9phrite Extra-Membraneuse, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"D\u00e9partement de N\u00e9phrologie, Dialyse et Transplantation, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Laboratoire d\u2019Immunologie, Unit\u00e9 de Th\u00e9rapie Cellulaire et G\u00e9nique, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Destere","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pharmacologie Clinique et de Pharmacovigilance, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Inria, CNRS, Laboratoire J.A. Dieudonn\u00e9, Maasai team, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Cremoni","sequence":"additional","affiliation":[{"name":"Institut de Recherche sur le Cancer et Vieillissement UMR7284 CNRS INSERM U1081, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Centre de R\u00e9f\u00e9rence Maladies Rares Syndrome N\u00e9phrotique Idiopathique et Glom\u00e9rulon\u00e9phrite Extra-Membraneuse, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"D\u00e9partement de N\u00e9phrologie, Dialyse et Transplantation, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Laboratoire d\u2019Immunologie, Unit\u00e9 de Th\u00e9rapie Cellulaire et G\u00e9nique, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e9vin","family":"Zorzi","sequence":"additional","affiliation":[{"name":"Institut de Recherche sur le Cancer et Vieillissement UMR7284 CNRS INSERM U1081, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Centre de R\u00e9f\u00e9rence Maladies Rares Syndrome N\u00e9phrotique Idiopathique et Glom\u00e9rulon\u00e9phrite Extra-Membraneuse, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"D\u00e9partement de N\u00e9phrologie, Dialyse et Transplantation, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Brglez","sequence":"additional","affiliation":[{"name":"Institut de Recherche sur le Cancer et Vieillissement UMR7284 CNRS INSERM U1081, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Centre de R\u00e9f\u00e9rence Maladies Rares Syndrome N\u00e9phrotique Idiopathique et Glom\u00e9rulon\u00e9phrite Extra-Membraneuse, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Laboratoire d\u2019Immunologie, Unit\u00e9 de Th\u00e9rapie Cellulaire et G\u00e9nique, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Benito","sequence":"additional","affiliation":[{"name":"EXACTCURE, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bailly","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Sant\u00e9 Publique, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Institut de Recherche sur le Cancer et Vieillissement UMR7284 CNRS INSERM U1081, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Centre de R\u00e9f\u00e9rence Maladies Rares Syndrome N\u00e9phrotique Idiopathique et Glom\u00e9rulon\u00e9phrite Extra-Membraneuse, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Laboratoire d\u2019Immunologie, Unit\u00e9 de Th\u00e9rapie Cellulaire et G\u00e9nique, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[{"name":"Institut de Recherche sur le Cancer et Vieillissement UMR7284 CNRS INSERM U1081, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Centre de R\u00e9f\u00e9rence Maladies Rares Syndrome N\u00e9phrotique Idiopathique et Glom\u00e9rulon\u00e9phrite Extra-Membraneuse, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"D\u00e9partement de N\u00e9phrologie, Dialyse et Transplantation, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"},{"name":"Laboratoire d\u2019Immunologie, Unit\u00e9 de Th\u00e9rapie Cellulaire et G\u00e9nique, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-C\u00f4te d\u2019Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2025121508054348000_15.4.e093920.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810457"},{"key":"2025121508054348000_15.4.e093920.2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11761116"},{"key":"2025121508054348000_15.4.e093920.3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-020117-043811","article-title":"Molecular Pathogenesis of Membranous Nephropathy","volume":"15","author":"Ronco","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"2025121508054348000_15.4.e093920.4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ekir.2022.10.008","article-title":"C5b-9 Glomerular Deposits Are Associated With Poor Renal Survival in Membranous Nephropathy","volume":"8","author":"Teisseyre","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025121508054348000_15.4.e093920.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"key":"2025121508054348000_15.4.e093920.6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ekir.2020.02.1033","article-title":"Complement Pathways in Membranous Nephropathy: Complex and Multifactorial","volume":"5","author":"Brglez","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2025121508054348000_15.4.e093920.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015"},{"key":"2025121508054348000_15.4.e093920.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1024068","article-title":"Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives","volume":"13","author":"Hartinger","year":"2022","journal-title":"Front Immunol"},{"key":"2025121508054348000_15.4.e093920.9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"2025121508054348000_15.4.e093920.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"key":"2025121508054348000_15.4.e093920.11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2025121508054348000_15.4.e093920.12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"key":"2025121508054348000_15.4.e093920.13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025121508054348000_15.4.e093920.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1292"},{"key":"2025121508054348000_15.4.e093920.15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040449"},{"key":"2025121508054348000_15.4.e093920.16","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11791018"},{"key":"2025121508054348000_15.4.e093920.17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.kint.2020.12.029","article-title":"Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy","volume":"99","author":"Delafosse","year":"2021","journal-title":"Kidney Int"},{"key":"2025121508054348000_15.4.e093920.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.803175","article-title":"A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis","volume":"12","author":"Arnold","year":"2021","journal-title":"Front Immunol"},{"key":"2025121508054348000_15.4.e093920.19","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1007\/s00415-022-11048-4","article-title":"Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis","volume":"269","author":"Du","year":"2022","journal-title":"J Neurol"},{"key":"2025121508054348000_15.4.e093920.20","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s40120-023-00481-w","article-title":"Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study","volume":"12","author":"Bruschi","year":"2023","journal-title":"Neurol Ther"},{"key":"2025121508054348000_15.4.e093920.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-023-03206-1","article-title":"Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Nephrol"},{"key":"2025121508054348000_15.4.e093920.22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00412","article-title":"Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial","volume":"7","author":"Brglez","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2025121508054348000_15.4.e093920.23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int"},{"key":"2025121508054348000_15.4.e093920.24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ekir.2023.10.023","article-title":"Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence","volume":"9","author":"Destere","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025121508054348000_15.4.e093920.25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016091022"},{"key":"2025121508054348000_15.4.e093920.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"2025121508054348000_15.4.e093920.27","unstructured":"TRUXIMA summary of product characteristics [Internet]. n.d. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/truxima-epar-product-information_en.pdf"},{"key":"2025121508054348000_15.4.e093920.28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/ndt\/gfac294","article-title":"Humoral and cellular responses after a third dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease","volume":"38","author":"Teisseyre","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025121508054348000_15.4.e093920.29","unstructured":"Protocole National de Diagnostic et de Soins de la Glom\u00e9rulon\u00e9phrite Extra-Membraneuse. 2022."},{"key":"2025121508054348000_15.4.e093920.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814427"},{"key":"2025121508054348000_15.4.e093920.31","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"key":"2025121508054348000_15.4.e093920.32","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020071091"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-093920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:05:52Z","timestamp":1765814752000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-093920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,2]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjopen-2024-093920"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-093920","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}